Norwegian cardiovascular biopharma Serodus has signed a merger agreement with Danish peptide specialist Phlogo to expand cardiovascular drug candidate portfolio.
Subject to approval by an EGM, the merger is expected to accelerate Serodus' commercialisation and development strategy with the addition of two first-in-class drug candidates SER130 and SER140.
SER130 is an IL-4 partial receptor agonist for Acute Myocardial Infarction (AMI) and SER140 is an IL-1 receptor antagonist for Type 2 diabetes.
Serodus CEO Eva Steines said," Phlogo's peptides SER130 and SER140 come from internationally-recognized researchers at Copenhagen University who have been concentrating on mimicking and inhibiting endogenous inflammatory cascades."
SER130 focuses on the severe tissue damage, which occurs after a heart attack, and SER140 is an anti-inflammatory drug candidate targeted at diabetes.
Phlogo CEO Torben Skarsfeldt said, "Phlogo has generated very interesting data on both compounds, but we were in a position where the company needed additional resources to continue the development."
